Hospital
Mccullough-Hyde Memorial Hospital, INC.
Mccullough-Hyde Memorial Hospital, INC. was paid $4.51M by Medicaid between Jan 2018 and Dec 2024, across 123 billing codes. Its largest line is 99283, emergency room visit (moderate) — 34% of everything it billed.
33Billing provider infoMCCULLOUGH-HYDE MEMORIAL HOSPITAL, INC.
OXFORD, OH 45056
OXFORD, OH 45056
33aNPI1245216183assigned 12/22/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.51M
24GClaims112,250
24DCodes billed123
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Ohio
Rank by total paid#88 of 101
Median peer was paid$22.32M
This provider vs. median0.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 9,138 | $334K | |
| 2019 | 8,729 | $332K | |
| 2020 | 5,114 | $321K | |
| 2021 | 9,062 | $463K | |
| 2022 | 12,382 | $623K | |
| 2023 | 36,243 | $1.37M | |
| 2024incomplete | 31,582 | $1.07M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 34% | 14,295 | 12,891 | $1.54M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 5,084 | 4,362 | $627K |
| 96361 | Intravenous infusion, hydration; each additional hour | 7.8% | 1,153 | 813 | $352K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.8% | 7,019 | 5,679 | $260K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.7% | 2,541 | 726 | $167K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 3.7% | 1,457 | 1,272 | $165K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.2% | 602 | 486 | $143K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.1% | 912 | 853 | $95K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.1% | 507 | 487 | $95K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.0% | 568 | 430 | $88K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.8% | 353 | 311 | $81K |
| 80053 | Comprehensive metabolic panel | 1.4% | 5,090 | 4,463 | $64K |
111 more codes
| 84443 | Thyroid stimulating hormone (TSH) | 1.2% | 2,473 | $56K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.2% | 425 | $54K |
| 99285 | Emergency room visit (most serious) | 1.1% | 467 | $49K |
| 99203 | Doctor's office visit, new patient (routine) | 1.0% | 944 | $45K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 789 | $44K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 442 | $40K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 808 | $38K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 10,101 | $35K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 987 | $32K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 674 | $27K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 93 | $27K |
| 80061 | Lipid panel | <1% | 1,808 | $24K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 872 | $22K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,304 | $22K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,118 | $22K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,632 | $21K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 430 | $17K |
| 87428 | <1% | 612 | $16K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 671 | $15K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 515 | $14K |
| 36415 | Collection of venous blood by venipuncture | <1% | 10,532 | $14K |
| G0378 | Hospital observation service, per hour | <1% | 140 | $13K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 538 | $13K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,382 | $12K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 81 | $11K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,249 | $11K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,597 | $10K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 28 | $8K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 271 | $7K |
| 84439 | <1% | 374 | $7K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,208 | $6K |
| 87806 | <1% | 179 | $6K | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 187 | $5K |
| 83540 | <1% | 505 | $5K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 14 | $5K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,175 | $4K |
| 85652 | <1% | 1,146 | $4K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 16 | $4K |
| 82728 | <1% | 160 | $3K | |
| 87430 | <1% | 457 | $3K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,769 | $3K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 181 | $3K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,766 | $2K |
| 82570 | <1% | 238 | $2K | |
| 81001 | <1% | 1,600 | $2K | |
| 80076 | <1% | 438 | $2K | |
| 85027 | <1% | 320 | $2K | |
| 87077 | <1% | 245 | $2K | |
| 83550 | <1% | 218 | $2K | |
| 86850 | <1% | 112 | $2K | |
| 87186 | <1% | 308 | $2K | |
| 82607 | <1% | 80 | $2K | |
| 73630 | <1% | 81 | $2K | |
| 86140 | <1% | 236 | $2K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 31 | $1K |
| 83735 | <1% | 679 | $1K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 19 | $1K |
| 59025 | Fetal non-stress test | <1% | 19 | $1K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 187 | $1K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 905 | $1K |
| 97162 | <1% | 15 | $1K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 35 | $1K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 41 | $981.12 |
| 81003 | <1% | 436 | $948.91 | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 15 | $930.02 |
| 96376 | <1% | 194 | $800.53 | |
| 86900 | <1% | 150 | $798.89 | |
| 86901 | <1% | 150 | $781.19 | |
| 87070 | <1% | 69 | $736.07 | |
| 82962 | <1% | 568 | $561.44 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 13 | $545.04 |
| 84153 | <1% | 29 | $534.85 | |
| 87071 | <1% | 51 | $485.57 | |
| 86762 | <1% | 28 | $466.10 | |
| 84484 | <1% | 1,115 | $441.28 | |
| 83690 | <1% | 940 | $382.72 | |
| J3490 | Unclassified drugs | <1% | 155 | $370.04 |
| 80320 | <1% | 55 | $370.00 | |
| 73130 | <1% | 13 | $327.20 | |
| 82043 | <1% | 45 | $310.78 | |
| 85610 | <1% | 158 | $303.26 | |
| 73610 | <1% | 13 | $269.82 | |
| 84702 | <1% | 18 | $196.02 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 985 | $194.83 |
| 83880 | <1% | 96 | $116.76 | |
| 81025 | <1% | 616 | $109.53 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 944 | $100.03 |
| 90715 | <1% | 14 | $87.10 | |
| 87205 | <1% | 16 | $76.43 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 578 | $50.67 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,135 | $46.17 |
| 85730 | <1% | 34 | $42.82 | |
| 83605 | <1% | 127 | $32.19 | |
| 82150 | <1% | 125 | $30.23 | |
| 84703 | <1% | 52 | $27.67 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 14 | $24.86 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 157 | $18.92 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,487 | $14.62 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 16 | $13.18 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 29 | $3.60 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 234 | $3.39 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 35 | $3.20 |
| J2704 | Injection, propofol, 10 mg | <1% | 516 | $2.16 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 49 | $0.33 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 15 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 37 | $0.00 |
| 4004F | 0% | 13 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 13 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 139 | $0.00 |
| 82803 | 0% | 33 | $0.00 | |
| 85379 | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCROFTON, MICHAEL (VICE PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| The Good Samaritan Hospital of Cincinnati, Ohio | Cincinnati, OH | $85.63M |
| Bethesda Hospital INC | Cincinnati, OH | $57.06M |
| Hospice of Cincinnati Incorporated | Cincinnati, OH | $54.08M |
| Trihealth G LLC | Cincinnati, OH | $30.89M |
| Trihealth H LLC | Cincinnati, OH | $12.50M |
| Trihealth U LLC | Cincinnati, OH | $209K |
| Trihealth HF LLC | Oxford, OH | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.